Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia.
作者信息
Konishi Yoshinobu, Sklavenitis-Pistofidis Romanos, Yue Hong, Ferrari Federico, Redd Robert A, Lightbody Elizabeth D, Russo Massimiliano, Perry Jacqueline, Horowitz Erica, Justis Anna V, Shayegh Nader A, Savell Alexandra, Prescott Julia, Varmeh Shohreh, Nowak Radosław P, Hamilton Mark, Auclair Daniel, Marinac Catherine R, Trippa Lorenzo, Fischer Eric S, Ghobrial Irene M
机构信息
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
出版信息
Cancer Cell. 2022 Jan 10;40(1):6-8. doi: 10.1016/j.ccell.2021.12.003. Epub 2021 Dec 9.
Abstract
摘要
相似文献
1
Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia.多发性骨髓瘤和华氏巨球蛋白血症无症状前驱期患者对SARS-CoV-2疫苗的反应减弱。
Cancer Cell. 2022 Jan 10;40(1):6-8. doi: 10.1016/j.ccell.2021.12.003. Epub 2021 Dec 9.
2
The 12-week kinetics of anti-SARS-CoV-2 antibodies in different haematological cancers after vaccination with BNT162b2.接种BNT162b2疫苗后不同血液系统癌症中抗SARS-CoV-2抗体的12周动力学
Br J Haematol. 2022 Jan;196(2):362-367. doi: 10.1111/bjh.17821. Epub 2021 Sep 6.
3
COVID-19 Vaccine Type and Humoral Immune Response in Patients Receiving Dialysis.接受透析患者的新冠疫苗类型与体液免疫反应
J Am Soc Nephrol. 2022 Jan;33(1):33-37. doi: 10.1681/ASN.2021070936. Epub 2021 Oct 13.
4
Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine.与完全接种 BNT162b2 疫苗的患者相比，感染 COVID-19 的骨髓瘤患者具有更高的抗体反应。
Br J Haematol. 2022 Jan;196(2):356-359. doi: 10.1111/bjh.17841. Epub 2021 Sep 16.
5
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose.骨髓瘤老年患者在接种第一剂BNT162b2疫苗后对新冠病毒的中和抗体反应较低。
Blood. 2021 Jul 1;137(26):3674-3676. doi: 10.1182/blood.2021011904.
6
Covid-19 vaccination in patients with multiple myeloma: Focus on immune response.多发性骨髓瘤患者的新冠病毒疫苗接种：关注免疫反应。
Am J Hematol. 2021 Aug 1;96(8):896-900. doi: 10.1002/ajh.26263. Epub 2021 Jun 21.
7
Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy.接受CAR T细胞疗法治疗的患者接种一剂和/或两剂BNT162b2抗SARS-CoV-2 mRNA疫苗后的安全性和抗体反应。
Br J Haematol. 2022 Jan;196(2):360-362. doi: 10.1111/bjh.17818. Epub 2021 Sep 2.
8
Immunogenicity Following Administration of BNT162b2 and Ad26.COV2.S COVID-19 Vaccines in the Pregnant Population during the Third Trimester.第三孕期孕妇接种 BNT162b2 和 Ad26.COV2.S COVID-19 疫苗后的免疫原性。
Viruses. 2022 Feb 2;14(2):307. doi: 10.3390/v14020307.
9
Humoral Response to mRNA versus an Adenovirus Vector-Based SARS-CoV-2 Vaccine in Dialysis Patients.透析患者对基于mRNA与腺病毒载体的SARS-CoV-2疫苗的体液反应。
Clin J Am Soc Nephrol. 2021 Nov;16(11):1720-1722. doi: 10.2215/CJN.06450521. Epub 2021 Jul 26.
10
Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.智利科兴和国药疫苗接种后动态 IgG 血清阳性率：哨点监测研究。
Lancet Infect Dis. 2022 Jan;22(1):56-63. doi: 10.1016/S1473-3099(21)00479-5. Epub 2021 Sep 9.
引用本文的文献
1
Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's Macroglobulinemia.单细胞RNA测序定义了不同的疾病亚型，并揭示了无症状华氏巨球蛋白血症对干扰素的低反应性。
Nat Commun. 2025 Feb 10;16(1):1480. doi: 10.1038/s41467-025-56323-w.
2
Development of a covalent cereblon-based PROTAC employing a fluorosulfate warhead.基于氟代硫酸弹头的共价结合脑啡肽酶的PROTAC的开发。
RSC Chem Biol. 2023 Aug 31;4(11):906-912. doi: 10.1039/d3cb00103b. eCollection 2023 Nov 1.
3
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).《后疫情时代多发性骨髓瘤合并 COVID-19 患者的管理：来自欧洲骨髓瘤网络（EMN）的共识文件》。
Leukemia. 2023 Jun;37(6):1175-1185. doi: 10.1038/s41375-023-01920-1. Epub 2023 May 4.
4
Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management.第五届瓦尔登斯特伦巨球蛋白血症第 11 次国际研讨会关于 COVID-19 预防和管理的共识小组报告。
Semin Hematol. 2023 Mar;60(2):107-112. doi: 10.1053/j.seminhematol.2023.03.004. Epub 2023 Mar 29.
5
A false positive serology test of SARS‑CoV‑2 in a patient with Waldenström's macroglobulinemia: A case report.华氏巨球蛋白血症患者出现严重急性呼吸综合征冠状病毒2（SARS-CoV-2）血清学假阳性检测结果：一例报告
Exp Ther Med. 2023 Mar 21;25(5):200. doi: 10.3892/etm.2023.11899. eCollection 2023 May.
6
Diagnostic TR-FRET assays for detection of antibodies in patient samples.用于检测患者样本中抗体的诊断 TR-FRET 分析。
Cell Rep Methods. 2023 Feb 20;3(3):100421. doi: 10.1016/j.crmeth.2023.100421. eCollection 2023 Mar 27.
7
Humoral Immune Response after anti-SARS-CoV-2 Vaccine "Booster" Dose in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).意义未明的单克隆丙种球蛋白病（MGUS）患者接种抗SARS-CoV-2疫苗“加强针”后的体液免疫反应
Mediterr J Hematol Infect Dis. 2023 Jan 1;15(1):e2023011. doi: 10.4084/MJHID.2023.011. eCollection 2023.
8
SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance.意义未明的单克隆丙种球蛋白病患者全程接种疫苗前后的新型冠状病毒2型感染发生率及转归
Hemasphere. 2022 Nov 9;6(12):e800. doi: 10.1097/HS9.0000000000000800. eCollection 2022 Dec.
9
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response.免疫应答：SARS-CoV-2 mRNA 疫苗接种和加强剂在多发性骨髓瘤和单克隆丙种球蛋白病患者中的作用：Omicron 变异对体液免疫应答的影响。
Oncoimmunology. 2022 Sep 6;11(1):2120275. doi: 10.1080/2162402X.2022.2120275. eCollection 2022.
10
Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis.COVID-19 疫苗加强针在血液系统恶性肿瘤和实体瘤患者中的应用：一项系统评价和个体化患者数据荟萃分析。
Eur J Cancer. 2022 Sep;172:65-75. doi: 10.1016/j.ejca.2022.05.029. Epub 2022 Jun 3.
本文引用的文献
1
Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma.多发性骨髓瘤完全接种疫苗患者对SARS-CoV-2的细胞反应各异。
Cancer Cell. 2021 Nov 8;39(11):1442-1444. doi: 10.1016/j.ccell.2021.09.015. Epub 2021 Oct 19.
2
Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies.血液系统恶性肿瘤患者对SARS-CoV-2疫苗的抗体反应。
Cancer Cell. 2021 Aug 9;39(8):1031-1033. doi: 10.1016/j.ccell.2021.07.012. Epub 2021 Jul 22.
3
Response to mRNA vaccination for COVID-19 among patients with multiple myeloma.mRNA 疫苗接种对多发性骨髓瘤患者 COVID-19 的反应。
Leukemia. 2021 Dec;35(12):3534-3541. doi: 10.1038/s41375-021-01354-7. Epub 2021 Jul 29.
4
Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of caution.癌症患者对 COVID-19 疫苗的免疫反应：有希望的结果和谨慎的提示。
Cancer Cell. 2021 Aug 9;39(8):1045-1047. doi: 10.1016/j.ccell.2021.07.001. Epub 2021 Jul 3.
5
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma.多发性骨髓瘤患者对两剂新冠病毒RNA疫苗的严重急性呼吸综合征冠状病毒2刺突抗体反应高度可变。
Cancer Cell. 2021 Aug 9;39(8):1028-1030. doi: 10.1016/j.ccell.2021.06.014. Epub 2021 Jun 29.
6
Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma.多发性骨髓瘤患者对严重急性呼吸综合征冠状病毒2首次疫苗接种的反应。
Lancet Haematol. 2021 Jun;8(6):e389-e392. doi: 10.1016/S2352-3026(21)00110-1. Epub 2021 Apr 19.
7
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma.单细胞 RNA 测序揭示多发性骨髓瘤前体阶段免疫微环境受损。
Nat Cancer. 2020 May;1(5):493-506. doi: 10.1038/s43018-020-0053-3. Epub 2020 Apr 27.
8
Dissecting racial disparities in multiple myeloma.剖析多发性骨髓瘤中的种族差异。
Blood Cancer J. 2020 Feb 17;10(2):19. doi: 10.1038/s41408-020-0284-7.
9
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.纳入修订后 IMWG 诊断标准的冒烟型多发性骨髓瘤的风险分层。
Blood Cancer J. 2018 Jun 12;8(6):59. doi: 10.1038/s41408-018-0077-4.
Zotero 插件